Introduction {#S1}
============

Chaperones in disease {#S2}
---------------------

Eukaryotes have evolved elaborate systems of chaperone proteins to cope with cellular stress. Under normal cellular conditions, chaperones regulate nascent protein folding. Cellular stressors, such as a thermal stress, can cause proteins to become unfolded, non-functional, or even structurally damaged. To maintain cellular homeostasis, the chaperone network will interact with these damaged "client" proteins and attempt to fold the protein back into a functional state or target the client for degradation. However, certain mutated or abnormally-modified disease-causing proteins are stabilized and maintained by the multitasking heat-shock protein 90 (Hsp90) and its co-chaperone network \[[@R1]-[@R3]\]. Such is the case in certain cancers, where the Hsp90 chaperone network facilitates disease by stabilizing oncogenic client proteins. It is now becoming clear that Hsp90 and its co-chaperones also regulate a majority of neurodegenerative proteinopathy ([Figure 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}).

A role for Hsp90 in the maintenance of neurodegenerative diseases is thought to be similar to its proposed role in cancer: mis-folding or stabilization of aberrant (neurotoxic) client- proteins. Because Hsp90 client-protein folding (and stabilization) is ATP-dependent, Hsp90 activity can be manipulated by ATP competitive small molecules. Indeed, the first known Hsp90 inhibitor, the antibiotic geldanamycin (GA), was discovered to compete with ATP for binding which stops the protein folding cycle and prevents client stabilization \[[@R4]-[@R7]\].

While these important biological roles propose a role for Hsp90 inhibitors in the treatment of neurodegenerative disease, it is also true that Hsp90 is one of the most abundantly (\~1-3% of total cellular protein) and ubiquitously expressed proteins. Such finding matches poorly with the belief that a good therapeutic target has to be of low expression in vital organs and tissues. Using the GA derivative 17-allylaminogeldanamycin (17-AAG), Kamal et al. provided the rationale for a therapeutic index for the use of Hsp90 inhibitors in disease. Specifically, they demonstrated the presence of high-ATP-affinity Hsp90 complexes seemingly exclusive to diseased cells. High-affinity species bound to these small-molecule ATPase inhibitors with nearly 100-fold higher affinity than Hsp90 from non-cancer cells \[[@R8]\]. This finding made GA, and similar inhibitors, both potently selective and therapeutically attractive.

Further work by Moulick et al. demonstrated that only a small percentage of the total cellular Hsp90 population exists in this high-affinity state \[[@R9]\]. It is thought that as the levels of intracellular aberrant proteins rise, so does the need for Hsp90; the cell's attempt to deal with accumulating proteins depends on greater Hsp90 activity. While the complete nature and composition of this high-affinity Hsp90 complex remain unclear, post-translational modifications \[[@R10]\] and binding of co-chaperones \[[@R9]\] to Hsp90 are likely involved. The shift to greater ATP- affinity and increased activity promotes the stabilization of pools of aberrant protein clients, possibly by passing them through folding cycles that are ultimately unproductive, stabilizing species whose fate should be degradation. This process facilitates and maintains many cancers and, as we show further here, many neurodegenerative diseases as well.

Aberrant proteins become clients of Hsp90 or are regulated by the Hsp90 chaperone network \[[@R9]\]. As mutant proteins continue to be experimentally recapitulated in cellular and animal models, much has been learned about the pivotal role of Hsp90 and its extensive co- chaperone network in the stabilization of aberrant client proteins. We will begin this review by examining tau as a model Hsp90 client, including the crucial role of Hsp70 in tau pathology.

These ideas will serve as a framework for subsequent discussion of aberrant proteins in other neurodegenerative diseases. We will evaluate experimental results from various cellular and animal disease models and discuss the therapeutic potential of pharmacologic intervention at the chaperone level. Lastly, we will propose a general model of chaperone dependency that links much seemingly-disparate neurodegenerative pathologies ([Figure 2](#F2){ref-type="fig"}).

Hsp90/Chaperone-dependent Tauopathies {#S3}
=====================================

Tau in neurodegeneration {#S4}
------------------------

The microtubule associated protein tau (MAPT) is a focal point of cellular regulation that integrates and responds to input from converging signaling cascades to regulate microtubule dynamics. Loss of microtubule function is detrimental to multiple neuronal systems including axonal transport, mitochondrial function, and autophagy \[[@R11]-[@R13]\]. In disorders featuring aberrant tau, a group collectively known as tauopathies, microtubule dysfunction is a common feature and this dysfunction has been suggested to be an initiating factor for the accumulation of tau. Tau affinity for microtubules is largely regulated by site-specific phosphorylation. The N-terminal acidic domain and C-terminal microtubule binding domain of tau flank a proline-rich middle region that is a target for pathogenic hyperphosphorylation by many proline-directed tau kinases. Tau exists as six isoforms each of which has a different affinity for microtubules \[[@R14],[@R15]\]. Two predominant groups are comprised of tau isoforms containing 3 or 4 microtubule-binding domain repeats in the C-terminus (3R or 4R). Tau mutations altering the 3R/4R tau ratio, normally about 1:1 \[[@R16]\], perturb tau proteostasis and can lead to microtubule destabilization and disease \[[@R17]\].

The phosphorylation and isoform specifics of tau are not the only factors that may drive tau pathogenicity. Tau mutations are responsible for a diverse group of neurodegenerative dementias that include Pick's disease, progressive supranuclear palsy (PSP) \[[@R18],[@R19]\], corticobasal degeneration (CBD) \[[@R20]-[@R22]\], and fronto-temporal dementia with parkinsonism linked to chromosome-17 (FTDP-17), a rare but devastating disease \[[@R23]\]. These disease-linked tau mutations affect tau phosphorylation and dephosphorylation \[[@R24],[@R25]\], which then alter tau affinity for microtubules \[[@R26]-[@R32]\]. These mutations also change the predilection of tau to aggregate into paired-helical filaments (PHF) and neurofibrillary tangles (NFT) \[[@R33]-[@R35]\]. For example tauP301L and tauP301S, two commonly-studied mutations, have each been linked to FTDP-17 \[[@R23],[@R36],[@R37]\]. Transgenic mice expressing human tau with these mutations accumulate hyperphosphorylated, insoluble tau and undergo cognitive and motor decline \[[@R38]-[@R44]\]. To date, more than 37 tau mutations have been associated with FTDP-17 \[[@R45]\]. Although NFTs comprised of insoluble tau are a hallmark of Alzheimer's disease, no tau mutations have yet been associated with AD. Finally, accumulation of tau and other neuronal disease-related proteins is thought to be exacerbated by age-dependent decline in protein degradation, as deficits in proteasomal processing and autophagy are observed in aging brains \[[@R46]\].

Perhaps the most remarkable aspect to tau pathogenesis is the fact that mutant tau fibrils can spread from cell to cell and confer a pathogenic conformation to normal tau, a process similar to intercellular prion seeding \[[@R47],[@R48]\]. Upon selective expression of tauP301L in the entorhinal cortex of mice, the origin of tau pathology in AD \[[@R49]\], pathogenic tau spread trans- synaptically through neuronal circuits in a temporal and spatial progression that mimics human disease \[[@R50]\]. These findings support the importance of developing reliable early diagnostic techniques for tau and also point to multiple steps of potential therapeutic intervention. As we shall see, they also raise questions about which steps are facilitated by chaperones.

In neurons, the breadth of tau function underlies the impact of its loss, or the loss of its normal functions. Once thought to be without phenotype because of redundancy found in related microtubule-binding proteins, tau knockout mice were recently shown to develop age- dependent brain atrophy and "parkinsonism-like" symptoms \[[@R51]\]. Interestingly, this degeneration was associated with a diminished neuronal iron transport mediated by amyloid precursor protein (APP), the protein processed into the aggregation-prone β-amyloid (Aβ) in Alzheimer's disease. Although neither APP nor Aβ has been confirmed as a bone fide Hsp90 client, *in vitro* studies suggest Aβ peptide aggregation can be influenced by Hsp90 and its co-chaperone Hsp70 \[[@R52],[@R53]\]. Additionally, studies in HEK cells suggest CHIP, Hsp70 and Hsp90 all participate in APP metabolism \[[@R54]\]. The Hsp90 chaperone network might also regulate drivers of Aβ production or aggregation \[[@R54],[@R55]\]. Importantly, most current models of AD pathology support a role for Aβ as a driver of tau pathology \[[@R56],[@R57]\] and a role for tau as the primary mediator of accumulating Aβ toxicity \[[@R58]-[@R60]\]. While the exact role of Hsp90 in Aβ pathology in AD remains unclear, Hsp90 and its co-chaperones play critical roles in facilitating tau pathology.

Hsp70/90 regulation of Tau proteostasis {#S5}
---------------------------------------

The first clues to Hsp70 and Hsp90 involvement in tau/microtubule regulation came in 2003 with the demonstration that higher levels of Hsp70 and Hsp90 correlated with lower levels of insoluble tau and increased tau-microtubule association \[[@R61]\]. In 2007, "high-ATP-affinity" Hsp90 complexes were discovered in the temporal cortex (an affected area) but not in the cerebellum (an unaffected area) of post-mortem brains from AD patients \[[@R62]\].

Before tau encounters Hsp90, though, it is bound by either Hsc70 or Hsp70, which control tau access to the proteasomal degradation machinery, the "triage decision". Following microtubule destabilization, tau first binds to the constitutively-expressed co-chaperone heat-shock cognate protein-70, Hsc70 \[[@R63]\]. Once this complex has formed, the aberrant client protein faces one of two fates: either folding or degradation. The client could be presented to Hsp90 through the scaffolding co-chaperone HOP (Hsp70/Hsp90 organizing protein) for attempted folding. Hsp90 interaction with either Hsc70 or Hsp70 may play opposing roles in facilitating accumulation of problem clients like tau: Hsc70 binding appears to stabilize tau and shelter it from degradation \[[@R63]\]. Also, the multi-functional modulator Bcl2-associated athanogene-1 (BAG-1) associates with the tau-Hsc70 complex and actually prevents proteasomal degradation of tau, a situation reversed by Hsp70 induction \[[@R64]\]. Hsp70-bound tau can be ubiquitinated by the E3-ubiquitin ligase CHIP (Hsc70-interacting protein) and targeted for proteasomal degradation \[[@R62],[@R65]-[@R68]\]. These finding suggest Hsp70 binding may favour tau degradation, whereas Hsc70 binding favours folding. Hsp70 and Hsc70 have been shown to have these opposing effects on other client proteins, as well \[[@R69]\]. These ideas are consistent with findings that Hsp70 differentially regulates tau isoforms and may function primarily in regulating dysfunctional tau isoforms \[[@R70]\].

Elegant biochemical studies by Kundrat and Regan demonstrate that CHIP binding to the Hsp70-client complex excludes HOP-Hsp90 binding \[[@R68]\]. Their in situ and *in vitro* analyses indicate that inhibition of Hsp90 causes client proteins to be degraded due to the expansion of the degradation pathway. Low cellular levels of Hsp70 and CHIP may control the basal levels of "house-keeping" turnover and degradation of tau, a pathway that is better accessed by tau when more Hsp70 is available to present tau to CHIP.

The potential for tau pathogenesis is also regulated by phosphorylation. This phospho- regulation of tau runs directly through the Hsp90 chaperone network. By chaperoning client kinases like glycogen synthase kinase (GSK3β), p35/CDK5 and microtubule affinity regulating kinase-2 (MARK2), three established tau kinases, the Hsp90 network controls the flow of signaling input to tau \[[@R53],[@R71]-[@R73]\]. Hsp90 co-chaperones like the immunophilin FKBP51/2 regulate tau folding and mediate kinase access to tau \[[@R74],[@R75]\], while another Hsp90 co- chaperone, protein phosphatase 5 (PP5), is a major tau phosphatase \[[@R73]\]. Thus Hsp90 acts as a nucleus for the complex regulatory machine that controls much of tau biology.

Chaperone Inhibition in Alzheimer's Disease and Tauopathy {#S6}
=========================================================

Inhibition of Hsp90 {#S7}
-------------------

The most promising Hsp90 inhibitors target the N-terminal ATPase domain \[[@R76]-[@R79]\]. Many novel and synthetic Hsp90 inhibitors are already in clinical trials, but at this point they are being tested primarily in cancer \[[@R80]-[@R82]\]. Research in the last decade revealed the therapeutic potential of Hsp90 inhibition in proteinopathic neurodegeneration \[[@R83],[@R84]\]. In early 2007, two studies demonstrated that Hsp90 inhibition decreases levels of hyperphosphorylated and/or mutated tau in cells and transgenic mice. Using the inhibitor EC102, Dickey et al. demonstrated selective degradation of hyperphosphorylated tau in both cells over-expressing tauP301L and in the human tau (hTau) mouse model \[[@R62],[@R85]\], which expresses all 6 human isoforms of tau and develops NFT and "Alzheimer-like" pathology \[[@R86]\]. Additionally, Hsp90 inhibition with EC102 selectively decreased tau phosphorylated at Ser/Thr sites thought to be controlled by the proline-directed kinases, likely GSK-3β and Cdk5 \[[@R62],[@R85],[@R87],[@R88]\]. Both kinases are known to participate in pathogenic tau phosphorylation while Akt, working with CHIP, also regulates tau degradation \[[@R89]\].

Also in early 2007, Luo et al. demonstrated that 17-AAG and the brain-permeable synthetic purine scaffold Hsp90 inhibitor, PU-DZ8, decreased levels of phosphorylated tau \[[@R90]\]. Importantly, not only does Hsp90 inhibition decrease levels of tau specifically phosphorylated on Ser202, a pathogenically-important site known to be phosphorylated by Cdk5, but also levels of the Cdk5-activator protein p35, which is itself a client of the Hsp90 chaperone network. Interestingly, while treatment of tauP301L mice with PU-DZ8 resulted in decreased soluble and insoluble tau, including mutant tau, treatment of hTau mice decreased Ser202-phosphorylated tau without affecting levels of endogenous tau \[[@R90]\].

As discussed, inhibition of Hsp90 in a system flooded with mis-folded client proteins has multiple beneficial effects. First, Hsp90 inhibition eliminates the folding pathway as an option for aberrant tau increasing the probability that tau will be ubiquitinated by CHIP and degraded. Second, Hsp90 inhibition initiates the HSF1-dependent heat-shock response and subsequent induction of Hsp70 and small heat-shock-protein (sHSP) \[[@R91]\]. Induction of Hsp70, normally expressed at very low levels, may increase tau degradation by out-competing Hsc70 for tau binding, thus giving aberrant tau a better chance at being ubiquitinated by CHIP, an E3 ubiquitin ligase ([Figure 1](#F1){ref-type="fig"}). Small HSP induction, particularly that of Hsp27, can also benefit neurons plagued with aberrant tau as recent work demonstrated that, when functional, Hsp27 was able to reduce tau burden in a transgenic-tau mouse model \[[@R92]\]. Hsp27 has also been shown to have neuroprotective effects against other drivers of AD pathology \[[@R93]\]. And third, many kinases that regulate tau are also clients of Hsp90. Indeed, it was recently shown that Hsp90 inhibition particularly impacts kinase stability \[[@R94]\]. Hsp90's role as a signaling node, connecting many regulatory pathways and regulating disease-specific processes, adds to its potential as a therapeutic target for inhibition in tau-based neurodegeneration: not only can the hyperphosphorylated tau be reduced but the kinases contributing to its persistent hyperphosphorylation can also be down-regulated. Thus, Hsp90 inhibition potential has greater efficacy than therapeutics that target single players in the processing pathways of these pathogenic proteins. When considered with decreased proteasome function or defective autophagy, as is suspected to occur in AD and many other neurodegenerative conditions \[[@R95]-[@R98]\], Hsp90 inhibition could reduce the tau burden from an overburdened and dysregulated regulatory system. As will be discussed later, similar regulatory systems may control the fates of other neurodegenerative proteins.

While these studies demonstrate the molecular effects of Hsp90 inhibition on tau degradation, validation of this therapeutic approach awaits the results of experiments designed to test these inhibitor's abilities to prevent and/or improve cognitive and behavioural deficits associated with tauopathies. Exactly how tau reduction will impact these functions is still unclear. Much will depend on the timing and duration of therapeutic intervention and how much neuronal damage has already occurred. These studies also highlight the critical role of Hsp90 in facilitating neurodegenerative phenotypes and they demonstrate how Hsp90 inhibition affects select client proteins through multiple pathways.

Therapeutic modulation of Hsp70 in AD {#S8}
-------------------------------------

Controlling the expression and activity of Hsp70 shows some promise in vitro and in cell models of tau-based neurodegeneration. Work from Dickey's group has identified both activators and inhibitors of Hsp70 activity \[[@R65],[@R69],[@R99]-[@R101]\]. Activation of Hsp70 increased tau stability, possibly by passing tau through an unproductive folding cycle. Conversely, Hsp70 inhibition reduced tau levels in cell-based models, perhaps by locking client tau and Hsp70 together, resulting in their ubiquitination and degradation \[[@R99]\]. They hypothesized that Hsp90 inhibition and the subsequent induction of Hsp70, followed by Hsp70 inhibition might be a potent strategy at reducing aberrant tau levels \[[@R65],[@R99]\].

It is important to note, however, that Hsp70 proteins are well-characterized protectors against stress-induced apoptosis \[[@R102]-[@R104]\]. Hsp70 and Hsc70 silencing seems to sensitize cancer cells to Hsp90 inhibition by reducing pro-apoptotic signaling \[[@R105]\]. While apoptotic outcomes are desirable in cancer, it seems unlikely that widespread neural apoptosis would benefit neurodegenerative diseases like AD. Indeed, Hsp70 limits apoptosis in neurons expressing mutant androgen receptor, the protein responsible for SBMA \[[@R106]\]. Thus strategies that inhibit Hsp70, especially after Hsp90 inhibition, may increase the risk of neural apoptosis. It will be important for future studies to determine the possible therapeutic risks and benefits of Hsp70 inhibition in patients with tauopathy.

Chaperones in Parkinson's Disease {#S9}
=================================

Alpha-synuclein, LRRK2 and the chaperone network {#S10}
------------------------------------------------

Alpha-synuclein is highly abundant in the pre-synaptic terminals of brain tissue \[[@R107]\]. It comprises the primary fibrillar component of Lewy body inclusions commonly found in Parkinson's disease (PD) patient brains \[[@R108]\] and its transgenic overexpression in mice facilitates neurodegeneration \[[@R109]-[@R112]\]. Postmortem analysis revealed that Hsp90, Hsc70 and Hsp40 co-localized with α-synuclein in Lewy bodies of α-synucleinopathy patients \[[@R113]\] and that CHIP and Hsp70 co-localized with α-synuclein in Lewy bodies of DLB patients \[[@R114]\]. Like tau, α-synuclein is an intrinsically disordered protein and can form oligomeric species that differ in size and shape \[[@R115]\] some of which can be toxic \[[@R116]-[@R118]\]. Mutations that promote α-synuclein aggregation \[[@R119]-[@R124]\] and α-synuclein duplications cause familial PD \[[@R125],[@R126]\]. Further, Hsp90, Hsp70 and CHIP interact with α-synuclein. Hsp90 can influence α-synuclein aggregation and vesicle binding; as was demonstrated in *in vitro* studies where Hsp90 binding to α-synuclein both abolished the ability of α-synuclein to bind to small unilamellar vesicles and promoted fibril formation in an ATP-dependent manner via oligomeric intermediates \[[@R127]\]. Indirect data support the notion that Hsp70 likely binds monomeric forms of soluble α-synuclein: following Hsp70 depletion, α-synuclein reactions resumed at a rate similar to the initial monomer-containing reactions \[[@R128]\]. CHIP, by co-immunoprecipitation, was also shown to interact with α-synuclein and Hsp70 in transfected H4 cells \[[@R129]\]. CHIP overexpression also reduced high molecular weight α-synuclein oligomers as well as mediated α-synuclein degradation via both proteasomal and lysosomal pathways in H4 cells \[[@R129]\]. While the field continues to explore possible mechanisms of α-synuclein-induced toxicity, in vitro studies suggest that Hsp90, Hsp70 and CHIP likely interact in a dynamic process to regulate α-synuclein fibril assembly and degradation.

Intraneuronal inclusions found in Parkinson's patients can also contain leucine-repeat- rich kinase 2 (LRRK2). The LRRK2G2019S substitution is the most common sporadic and inherited PD-causing mutation and is associated with dominantly inherited PD \[[@R130]-[@R133]\]. Mechanisms similar to, yet distinct from, α-synuclein aggregation may govern the function and stability of LRRK2 in Parkinson's disease. As with α-synuclein, Hsp90, Hsp70 and CHIP also interact with LRRK2. Several LRRK2 proteomic studies have independently verified that LRRK2 binds to Hsp90 \[[@R134]-[@R137]\]. Lichtenberg et al. found that Hsp70 overexpression in COS-7 cells decreased LRRK2 aggregation \[[@R138]\] but did not influence levels of soluble LRRK2. LRRK2 expression in Zebrafish embryos increased GFP ubiquitination. The authors suggested that LRRK2 is more accessible in the presence of Hsp70 and that certain LRRK2 species, such as LRRK2 mono- or oligomers may mediate the accumulation of other proteins. CHIP can bind to multiple LRRK2 domains and promote LRRK2 degradation in HEK293 cells \[[@R134]\]. Further, Hsp90 and CHIP activity levels are determinants of LRRK2-mediated toxicity \[[@R134],[@R139]\]. CHIP overexpression and increased LRRK2 degradation rates in HEK293 cells \[[@R134]\] and also reduced LRRK2-mediated toxicity in SH-SY5Y cells and HeLa cells.

Hsp90 inhibition in parkinson's disease models {#S11}
----------------------------------------------

Multiple in vitro studies determined that small molecule Hsp90 inhibitors have the potential to treat Parkinson's disease. In human H4 neuroglioma cells, Hsp90 inhibitors reduced α-synuclein-induced toxicity \[[@R140],[@R141]\]. Hsp90 inhibitors also rescued the axonal growth retardation caused by LRRK2G2019S in primary mouse cultured cortical neurons \[[@R142]\].

Additionally, Hsp90 inhibition reduced the toxicity mediated by LRRK2G2019S and LRRK2R1441C in transfected HeLa cells \[[@R139]\].

*In vivo* studies in PD models have been limited, perhaps largely because researchers are still in the process of developing and refining effective brain-permeable Hsp90 inhibitors. Hsp90 inhibitors prevented α-synuclein oligomer formation in culture \[[@R140]\] but the in vivo effects on α-synuclein have not been reported. Hsp90 inhibition rescued α-synuclein induced toxicity in Drosophila \[[@R84]\]. Further, a MPTP-damage mouse model of PD also revealed neuroprotective effects of Hsp90 inhibition \[[@R143]\].

While Hsp90 inhibitors have shown great promise for reducing protein levels, it is important to note that a number of PD-causing mutations are the result of inactive or under- functioning domains. For example, PTEN-induced kinase 1 (Pink1) PD-causing mutations likely reduce Pink1 activity \[[@R144]-[@R146]\] are linked to familial PD and Pink1 haplo-insufficiency is linked to idiopathic PD \[[@R147]-[@R149]\]. Pink-1 is an Hsp90 client \[[@R150],[@R151]\] and its function may rely partly on its interaction with Hsp90. Additionally, loss-of-function mutations in parkin, an E3 ubiquitin ligase similar to CHIP, are causative factors in some familial PD \[[@R152]\]. If loss-of-function proteins are drivers of α-synucleinopathies like Parkinson's disease, the potential in vivo benefits of Hsp90 inhibitors still exist as Hsp90 inhibition drives pro-clearance pathways regardless of client functionality.

In addition to directly modulating Hsp90 clients, Hsp90 inhibitors may exert indirect protective effects resulting from HSF-1 activation and subsequent Hsp70 induction. In Drosophila and yeast models of PD, directed expression of Hsp70 or heat shock (presumably through Hsp70 induction) limited α-synuclein cytotoxicity \[[@R84],[@R153]\]. Hsp70 can also prevent pre- fibrillar α-synuclein formation \[[@R128],[@R154]\] and reduce LRRK2 aggregation \[[@R138]\].

Chaperones and Amyotrophic Lateral Sclerosis ALS {#S12}
================================================

Amyotrophic lateral sclerosis (ALS) is a fatal degenerative disease of upper and lower motor neurons and the average lifespan for patients with ALS is only 3-5 years after diagnosis. Currently, over 250 mutations in 11 genes have been linked to a spectrum of familial (fALS) and sporadic forms of ALS \[[@R155],[@R156]\]. Once thought to be more than 95% sporadic, it has been argued that many fALS cases are likely misreported as sporadic and should more properly be referred to as isolated ALS (iALS) \[[@R155]\]. Recent molecular analyses indicate a majority of familial ALS is caused by mutations in one of three proteins: the Cu/Zn superoxide dismutase SOD1 or one of two RNA-processing proteins, TAR-DNA-binding protein-43 (TDP-43) or fused- in-sarcoma (FUS), the last two of which are also linked to FTLD \[[@R157]\]. As with tauopathies and Parkinson's disease, evidence supports a chaperone-mediated hypothesis of disease for much of ALS. Most importantly, therapeutic strategies that inhibit Hsp90 and increase Hsp70 activity show promise in some cellular and animal ALS models.

SOD1 {#S13}
====

Since mutant SOD1 was first associated with insoluble intracellular inclusions from familial ALS (fALS) patients \[[@R158]\], it is now estimated that 20% of fALS is associated with SOD1 mutations \[[@R159]\]. SOD1 normally protects cells from oxidative damage, dismutating the free radical superoxide to oxygen and hydrogen peroxide. Disease-related SOD1 mutations are thought to confer a gain-of-function, as mice expressing dismutase-inactivated SOD1 develop ALS \[[@R160]\]. While many theories have been proposed to explain SOD1-mediated neurodegeneration, it likely arises from disruption of multiple cellular systems including metabolic signaling and metal homeostasis \[[@R161],[@R162]\]. Interestingly, the contribution of aberrant SOD1 to disease depends on the cell type expressing SOD1: neuronal SOD1 influences disease genesis while astrocyte and microglial expression can accelerate disease progression \[[@R163]-[@R166]\].

Similar to aberrant proteins in other neurodegenerative diseases, mutant SOD1 is a client of the Hsp70/Hsp90 chaperone network \[[@R167]\], and its proteasomal degradation is largely regulated by the ubiquitin ligase CHIP \[[@R167]-[@R169]\]. Ubiquitinated SOD1 is a primary component in the intraneuronal aggregates in some ALS \[[@R158]\]. Hsc70 is commonly found associated with these aggregates \[[@R170],[@R171]\]. This might suggest the possibility of a situation similar to that of tau and Hsc70 \[[@R64]\]: Hsc70 might protect SOD1 from proteasomal degradation and facilitate its accumulation \[[@R64]\], while Hsp70 binding might favor SOD1 ubiquitination and degradation. In cultured motor neurons expressing mutant SOD1, increasing levels of Hsp70 decreased aggregation of SOD1 and attenuated toxicity \[[@R172],[@R173]\]. Raising Hsp70 levels by overexpression \[[@R174]\], increased HSF-1 activity or Hsp90 inhibition with 17-AAG was cytoprotective and decreased mutant SOD1 levels in primary motor neuron cultures \[[@R175]\]. Conversely, Liu et al. reported no benefit from over-expression of Hsp70 in mutant SOD1 mice \[[@R176]\]. Taken together, these results might suggest that in cellular models of SOD1-based ALS, increasing Hsp70 activity is sufficient to decrease SOD1 aggregation and limit neurotoxicity. However, in vivo models of ALS appear to benefit more from the induction of a generalized Hsf1-dependent heat-shock response. The compound arimoclomol, a "co-inducer" of the heat- shock response, reduced aggregated SOD1, delayed disease progression and increased lifespan in mutant SOD1 mice \[[@R177],[@R178]\]. Recent Phase II and Phase III clinical trials with arimoclomol in SOD1-fALS patients ended and the results are expected in the near future.

TDP-43 and FUS {#S14}
==============

A break-through in our understanding of ALS began last decade when insoluble, ubiquitinated RNA-binding protein TDP-43 was discovered in patients with ALS and FTLD \[[@R179],[@R180]\]. Soon thereafter, mutated TDP-43 was linked to both fALS and iALS \[[@R181]-[@R183]\]. After mutations in a structurally similar RNA-binding protein, FUS, were also linked causatively to fALS \[[@R184],[@R185]\], RNA processing gained wider attention in neurodegenerative research. Many recent studies implicate both loss- and gain-of-function toxic effects in TDP-43/FUS pathogenicity. TDP-43 normally regulates expression and splicing of mRNA transcripts longer than 1000 kilobases \[[@R186]\], including transcripts for proteins involved in synaptic function like the N-methyl-D-aspartate (NMDA) receptor and transcripts for proteins implicated in neurodegeneration like tau, parkin, huntingtin, the ataxin proteins and FUS \[[@R186]-[@R188]\]. TDP-43 and FUS are binding partners that may act in concert to promote toxicity. ALS-linked TDP-43 mutations increase protein stability and increase its association with FUS \[[@R189]\]. A complex of the two proteins inhibits cell growth in yeast \[[@R190]\] and impacts movement and lifespan in Drosophila \[[@R191]\], effects possibly mediated by co-regulation of histone deacetylase 6 (HDAC6) mRNA \[[@R192]\].

TDP-43 disease pathology appears to be controlled by the Hsp90 chaperone network. In a Drosophila model of ALS, 17-AAG treatment decreased and redistributed TDP-43 and decreased levels of its toxic proteolytic product TDP-25 \[[@R193]\]. Indeed, neurotoxicity of the TDP- 43A315T mutant in Drosophila was mitigated by Hsp70 over-expression \[[@R194]\]. These results suggest a regulatory role for Hsp70 and Hsp90 in TDP-43 proteostasis and pathogenicity either directly or indirectly. While much remains to be elucidated about the nature and regulation of these disease-causing proteins, these studies highlight the importance of Hsp90 and its extensive co-chaperone machinery in ALS disease processes.

Chaperones and Polyglutamine Diseases {#S15}
=====================================

Some of the earliest clues to chaperone involvement in neurodegeneration came when the Hsp90 co-chaperones Hsp70 and Hsp40 were linked to polyglutamine-expansion (polyQ) diseases. These neurodegenerative diseases involve cytotoxic accumulation of a mutated protein that contains expanded tracts of glutamine residues. Increased CAG nucleotide repeats forming a series of uninterrupted glutamines disrupts native protein structure and promotes aggregate formation.

Polyglutamine expansion of ataxin proteins causes spinocerebellar ataxia (SCA), a spectrum of progressive neurodegenerative diseases currently attributed to mutations in over 29 genes \[[@R195]\]. Much evidence suggests the Hsp90 chaperone network regulates mutant ataxin biology. Early results from cell models demonstrated Hsp70 and Hsp40 prevented in situ aggregation of mutant ataxin-1 (SCA1) \[[@R196]\]. Overexpression of Hsp70 was also shown to provide neuroprotection in two in vivo models of CAG-expansion ataxia \[[@R197],[@R198]\]. The proteasomal degradation of both ataxin-1 and ataxin-3 is controlled by CHIP-ubiquitination \[[@R199]-[@R202]\], an interaction mediated under stress conditions by Hsp70 \[[@R199]\]. Samples taken from patients with spinocerebellar ataxia type-7, another polyQ disease brought on by CAG repeats, demonstrated decreased expression of two major heat shock proteins, Hsp70 and Hsp27 \[[@R203]\]. Other groups have also demonstrated that expression of Hsp70 can be beneficial, or lack-there- of detrimental, in select polyQ ataxin disorders \[[@R204],[@R205]\]. The observed neuroprotection combined with the genetic suppression suggests that induction of Hsp70 could be beneficial in cases of polyQ expanded ataxins.

Chaperone modulation also limited aggregation of mutant polyQ androgen receptor in cellular models of spinal and bulbar muscular atrophy (SBMA) \[[@R106],[@R206]\], a slowly-progressive X-linked neurodegenerative disease. In 2005, Waza et al. provided the first evidence of high- ATP-affinity Hsp90 in neurodegenerative disease, when they showed 17-AAG bound to a complex of Hsp90 and mutant androgen receptor in both cellular and mouse SBMA models \[[@R207]\]. Additionally, treatment with the orally-bioavailable GA derivative 17- (dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) limited cellular damage and improved motor function in SBMA mice \[[@R208]\]. It is important to note that Hsp90 inhibition caused specific degradation of mutant androgen receptor and did not affect levels of wild-type receptor. Perhaps not surprisingly, Hsp90 inhibition prevented aggregation of mutant androgen receptor in a cellular model that lacked Hsf1 and could not initiate a heat-shock response upon Hsp90 induction \[[@R209]\]. However, in a SBMA mouse model, overexpression of Hsp70 was able to improve the phenotype by reducing the levels of the mutant AR \[[@R210]\]. This finding suggests that Hsp90 inhibitors would be able to improve the health of neurons expressing mutant AR by both Hsp90 inhibition and concurrent Hsp70 induction.

Perhaps the best-known polyQ disease is Huntington's disease, characterized by the aggregation of the multi-functional huntingtin protein. Similar to the other polyglutamine- expansion diseases, increasing cellular Hsp70 and Hsp40 levels limited abnormal huntingtin aggregation \[[@R211]\]. Inhibition of Hsp90 and Hsp70 also reduced aggregation of huntingtin \[[@R83],[@R212],[@R213]\], which was recently confirmed as an Hsp90 client \[[@R214]\]. Interestingly, huntingtin degradation is also regulated by CHIP \[[@R215],[@R216]\]. Increasing the levels of CHIP reduced both huntingtin aggregation and aggregation-dependent apoptosis \[[@R201]\]. Similar to many other chaperone-dependent neurodegenerative diseases we've discussed, Hsc70 is commonly observed associated with insoluble huntingtin cellular and brain aggregates \[[@R217]\]. In a *Saccharomyces cerevisae* model of huntingtin aggregation other heat shock proteins including Hsp26 and Hsp104 interacted with huntigntin \[[@R218]\]. Additionally, BAG1, the same protein that influences tau fate through Hsc70 binding, may be playing a similar role in determining the aggregation fate of huntingtin \[[@R219]-[@R224]\].

All of these results suggest that chaperones play critical roles in facilitating the accumulation of mutated proteins in polyglutamine expansion diseases. The possible roles of Hsp70 and Hsp90 in this disease system are strikingly similar to their suspected roles in facilitating tauopathy and other neurodegenerative diseases. However, while Hsp90 inhibition and increased Hsp70 expression have shown promise in alleviating toxic pathology of the polyglutamine diseases in both cellular and animal models, their effectiveness as therapeutic strategies awaits validation in clinical trials.

Conclusions {#S16}
===========

As reviewed here, the Hsp90 chaperone network likely facilitates many proteinopathic neurodegenerative diseases. Basal disease conditions dominated by constitutive Hsc70 expression favour the binding of aberrant clients to Hsc70. This client/Hsc70 complex then presents the client to Hsp90 for (presumably) unsuccessful folding. Since Hsc70 is commonly associated with insoluble client aggregates, we can surmise that, during disease conditions, Hsc70 binding to aberrant clients favours client accumulation and aggregation. Upon Hsp90 inhibition, however, two important changes take place. First, the folding pathway of Hsp90 is eliminated as an option, shunting the flow of cycling clients toward degradation pathways. Second, Hsp70 expression is greatly increased with the induced heat-shock response. Experimental evidence shows that Hsp70 binding results in aberrant client degradation, most likely by increasing the possibility that the Hsp70-client complex will be ubiquitinated by CHIP and eventually degraded. While increasing Hsp70 expression alone can decrease levels of aberrant client proteins, results from both cell and animal models of neurodegeneration suggest that the greatest benefit comes from Hsp90 inhibition and the combined actions of stopping client folding and increasing Hsp70 expression. Thus, pharmacologic inhibition of Hsp90 and induction of a neuroprotective heat-shock response have a two-pronged effect on aggregating neurodegenerative clients, in that the inhibition breaks the "non-functional folding cycle" driven by Hsp90 and the subsequent induction of HSPs increases the presence of the pro-degradation Hsp70 ([Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}).

The role of the Hsp90 chaperone network machinery in the regulation of aberrant proteins makes it a prime therapeutic target in treating the spectrum of neurodegenerative diseases ([Table 1](#T1){ref-type="table"}). While Hsp90 inhibitors clearly show therapeutic potential in multiple animal models expressing mutant aggregating proteins, it remains uncertain whether they will prove similarly successful in the larger number of patients with idiopathic disease. Despite this, mounting evidence suggests that most of these neurodegenerative models also benefit from induction of the heat-shock response and/or increased expression of Hsp70 and the subsequent degradation of problem proteins. This offers some hope that these processes may be generalized to many proteinopathic neurodegenerative diseases. Much work remains to fully elucidate the roles of Hsp90 network chaperones in neurodegenerative disease. Experimental results from the last decade speak to the potential of chaperone manipulation, specifically Hsp90 inhibition and up-regulation of Hsp70, as promising therapeutic paradigms that may be applicable across a broad range of neurodegenerative disease.
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![Inhibition of Hsp90 generates two distinct mechanisms both of which result in client protein degradation and enhanced cell survival. Pathogenic Hsp90 "client" proteins are dependent on Hsp90 for nascent folding and maintenance of structure. Upon Hsp90 inhibition, client proteins, including those involved in disease lose stability and are degraded. Hsp90 inhibition also promotes the induction of other heat shock proteins through an HSF1 dependent mechanism. These HSPs can also promote clearance and block aggregation of aberrant clients while enhancing cell survival under the "stressed" condition.](nihms553855f1){#F1}

![Protein folding pathways can prove to be detrimental when the chaperone folding machinery fails to properly process an aberrant aggregation-prone client protein. Under the condition of Hsp90 inhibition, Hsp90 is removed from the unproductive folding equation, disrupting this pro-aggregation pathway. Also, inhibition of Hsp90 induces the HSPs, including Hsp70. Increased levels of Hsp70 can facilitate a higher incident of interaction between client and pro-degradation pathway. As an example, interaction of a client with an ubiquitin ligase promotes proteasomal degradation of aberrant clients rather than accumulation and aggregation.](nihms553855f2){#F2}

###### 

Shows Inhibition of Hsp90 and Hsp 70 which generates two distinct mechanisms both of which result in client protein degradation and enhanced cell survival.

  Protein                 Associated Neurodegenerative disease   Benefit from Hsp70 elevation *in vitro*?   Benefit from Hsp70 elevation *in vivo*?   Benefit from Hsp90 inhibition *in vitro*?   Benefit from Hsp90 inhibition *in vivo*?
  ----------------------- -------------------------------------- ------------------------------------------ ----------------------------------------- ------------------------------------------- ------------------------------------------
  **Tau**                 Tauopathies (AD, CBD, PSP, FTDP-17)    Yes \[[@R61]\]                             Yes \[[@R61]\]                            Yes \[[@R62],[@R90]\]                       Yes \[[@R62],[@R90]\]
  **α-synuclein**         PD, DLB, MSA                           Yes \[[@R220]\]                            ?                                         Yes\[[@R127],[@R221]\]                      Yes \[[@R140]\]
  **LRRK2**               PD                                     Yes \[[@R138]\]                            ?                                         Yes \[[@R139]\]                             ?
  **SOD1**                ALS                                    Yes \[[@R172]-[@R174]\]                    No \[[@R176]\]                            Yes \[[@R175]\]                             ?
  **TDP-43**              ALS/FTD                                Yes \[[@R222]\]                            Yes \[[@R194]\]                           Yes \[[@R223]\]                             Yes \[[@R193]\]
  **Huntingtin**          HD                                     Yes \[[@R211]\]                            No \[[@R212]\]                            Yes \[[@R83]\]                              Yes \[[@R212]\]
  **Androgen receptor**   SBMA                                   Yes \[[@R106],[@R206]\]                    Yes \[[@R210],[@R224]\]                   Yes\[[@R207],[@R209]\]                      Yes \[[@R207],[@R208]\]
  **Ataxins**             SCA                                    Yes \[[@R196]\]                            Yes \[[@R197],[@R198]\]                   ?                                           ?
